The Journal of Clinical Endocrinology & Metabolism · 2013 · 240 citations · 19 references
Life SciencesBiochemistryDiabetologyMetabolismMetabolomicsDiabetes MellitusMass SpectrometryMass Spectrometry-based MetabolomicsMetabolite AnnotationMetabolite ProfilingUntargeted MetabolomicsGas Chromatography-mass SpectrometryGlucose Metabolism BiomarkersImpaired Glucose ToleranceLiquid Chromatography-mass SpectrometryMass Spectrometry-based Metabolite ProfilingMetabolic Signature DiscoveryMetabolomic ChangesMetabolomic Signatures
OBJECTIVE: Metabolic profiling of small molecules offers a snapshot of physiological processes. To identify metabolic signatures associated with type 2 diabetes and impaired fasting glucose (IFG) beyond differences in glucose, we used mass spectrometry-based metabolic profiling. RESEARCH DESIGN AND METHODS: Individuals attending an institutional health screen were enrolled. IFG (n = 24) was defined as fasting glucose (FG) of 6.1 to 6.9 mmol/L and 2-hour post glucose load <11.1 mmol/L or glycosylated hemoglobin <6.5%, type 2 diabetes (n = 27), FG ≥7.0 mmol/L, or 2-hour post glucose load ≥11.1 mmol/L, or glycosylated hemoglobin ≥6.5%, and healthy controls (n = 60), FG <6.1 mmol/L. Fasting serum metabolomes were profiled and compared using gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry. RESULTS: Compared to healthy controls, those with IFG and type 2 diabetes had significantly raised fructose, α-hydroxybutyrate, alanine, proline, phenylalanine, glutamine, branched-chain amino acids (leucine, isoleucine, and valine), low carbon number lipids (myristic, palmitic, and stearic acid), and significantly reduced pyroglutamic acid, glycerophospohlipids, and sphingomyelins, even after adjusting for age, gender, and body mass index. CONCLUSIONS: Using 2 highly sensitive metabolomic techniques, we report distinct serum profile change of a wide range of metabolites from healthy persons to type 2 diabetes mellitus. Apart from glucose, IFG and diabetes mellitus are characterized by abnormalities in amino acid, fatty acids, glycerophospholipids, and sphingomyelin metabolism. These early broad-spectrum metabolic changes emphasize the complex abnormalities present in a disease defined mainly by elevated blood glucose levels.
19
Metabolite profiles and the risk of developing diabetes
Thomas J. Wang, Martin G. Larson, Ramachandran S. Vasan et al. · Nature Medicine · 2011 · 3.1K citations · Full text
Pengxiang She, Cynthia Van Horn, Tanya Reid et al. · American Journal of Physiology-Endocrinology and Metabolism · 2007 · 506 citations · Full text